Cancer Medicine (Dec 2022)

Spirometry at diagnosis and overall survival in non‐small cell lung cancer patients

  • Ting Zhai,
  • Yi Li,
  • Robert Brown,
  • Michael Lanuti,
  • Justin F. Gainor,
  • David C. Christiani

DOI
https://doi.org/10.1002/cam4.4808
Journal volume & issue
Vol. 11, no. 24
pp. 4796 – 4805

Abstract

Read online

Abstract Pulmonary function can predict all‐cause mortality, and chronic obstructive pulmonary disease (COPD) is associated with worse overall survival (OS) in non‐small cell lung cancer (NSCLC) patients. Though pre‐operative lung function is predictive of in‐hospital mortality following lung cancer surgery, its predictive utility for long‐term survival is unclear. The prognostic role of commonly used spirometry tests in survival of lung cancer also remains uncertain. This study evaluates the role of spirometry at lung cancer diagnosis in predicting OS of NSCLC patients. This was a retrospective study using data from the Boston Lung Cancer Study on newly diagnosed NSCLC patients with spirometry tests performed before cancer therapy (n = 2805). Spirometric test values, after being categorized using quartiles, were analyzed for association with OS using univariate and risk‐adjusted multiple regression models. Further, we analyzed OS by the status of COPD determined by spirometry, and, among those with COPD, by its stage defined by the Global Initiative for Chronic Obstructive Lung Disease criteria. Both univariate and multiple regression models demonstrated that lower quartiles of actual and percent predicted forced expiratory volume in 1 second and forced vital capacity at lung cancer diagnosis were significantly associated with worse OS. Spirometry‐determined COPD, and more advanced stage of COPD at lung cancer diagnosis were associated with worse lung cancer OS. The findings provide evidence that a good pulmonary function at diagnosis may help improve OS in NSCLC patients.

Keywords